Liquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Your Basket's Financial Footprint
Summary of the basket's total market capitalisation and concentration by large-cap constituents.
- Large-cap dominance suggests generally lower volatility and more stable returns, often tracking broader market moves.
- Suitable as a core holding for portfolio stability rather than a speculative, high-risk growth allocation.
- Likely to deliver steady long-term value rather than explosive short-term gains.
GH: $8.42B
EXAS: $12.00B
VCYT: $2.84B
- Other
About This Group of Stocks
Our Expert Thinking
We've identified companies pioneering blood-based cancer testing that could fundamentally transform oncology care. These technologies enable detection of cancer's genetic signatures from simple blood draws, potentially shifting treatment from late-stage intervention to early detection when outcomes are better and costs are lower.
What You Need to Know
This collection offers growth potential by targeting the expanding medical diagnostics sector. Companies range from established market leaders to promising biotech innovators. The sector is gaining momentum as regulatory approvals increase and insurance companies expand coverage, validating these technologies.
Why These Stocks
These companies were handpicked based on their leadership in developing non-invasive cancer diagnostics, commercial success of existing products, or promising late-stage clinical pipelines. Each represents a strategic position in the evolution toward blood-based testing that could redefine cancer screening and monitoring.
Why You'll Want to Watch These Stocks
Medical Breakthrough Potential
These companies are developing technology that could revolutionize how we detect and monitor cancer. Early detection means better outcomes, creating both healthcare impact and significant profit potential.
Simple Blood Test, Massive Market
Imagine detecting cancer with just a routine blood draw. This simplicity is driving rapid adoption that could capture billions from traditional diagnostic methods and create entirely new screening markets.
Regulatory Momentum Building
FDA approvals and insurance coverage are accelerating for these technologies. Each new approval can trigger significant stock movements as companies transition from research phase to commercial revenue growth.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Walmart Succession Plan Explained | Market Effects
Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.
Biotech Buyout Candidates (Post-Merck Acquisition)
Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.
Cybersecurity Stocks Navigate US-China Tensions 2025
A White House memo reportedly accused Alibaba of supporting the Chinese military, intensifying the tech rivalry between the two superpowers. This escalating geopolitical tension highlights a critical need for robust cybersecurity, creating investment opportunities in companies that protect against state-level digital threats.